We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing oral treatments for chronic metabolic and pulmonary conditions. It develops oral small molecule therapeutics for the treatment of various diseases, including those impactin... Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing oral treatments for chronic metabolic and pulmonary conditions. It develops oral small molecule therapeutics for the treatment of various diseases, including those impacting the metabolic, cardiovascular, and pulmonary systems. Its initial focus is on G-protein-coupled receptors as a therapeutic target class. It is developing GSBR-1290, its oral small molecule product candidate targeting the validated glucagon-like-peptide-1 receptor for the treatment of type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases. Specifically, it is advancing ANPA-0073, its biased agonist, targeting the apelin receptor. It is also developing LTSE-2578, an investigational oral small molecule LPA1R antagonist for the treatment of idiopathic pulmonary fibrosis. Show more
As filed with the Securities and Exchange Commission on March 8, 2024 Registration No. 333- UNITED...
SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics...
0.815.5111019800095840000001888886FY001920000019200000128000001280000000003285700032857000216100021610000010527000139220000P2Y0.759812438false0001888886gpcr:ShareExchangeAgreementWithSubsidiariesMe...
false 0001888886 True 0001888886 2024-03-08 2024-03-08 0001888886 gpcr:AmericanDepositarySharesAdssEachRepresentingThreeOrdinarySharesParValue0.0001Per...
Topline GSBR-1290 Phase 2a 12-week obesity data, as well as data from formulation bridging and titration optimization study, on track for latter half of the second quarter 2024 Phase 2b study in...
false 0001888886 True 0001888886 2023-12-18 2023-12-18 0001888886 gpcr:AmericanDepositarySharesAdssEachRepresentingThreeOrdinarySharesParValue0.0001Per...
GSBR-1290 was generally well-tolerated with no treatment-related serious adverse events over 12 weeks; 2.8% study discontinuation rate due to adverse events related to study drug in diabetes and...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions